Natco Pharma Ltd.

Further to its earlier intimation dated November 2, 2023 about the successful completion of United States Food and Drug Administration’s (USFDA) inspection of the firm’s compliance to Pharmacovigilance requirements with zero observations, NATCO Pharma has informed that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed.

The above information is a part of company’s filings submitted to BSE.